ArticleNPJ vaccines2025
Trehalose-loaded LNPs enhance mRNA stability and bridge in vitro in vivo efficacy gap.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- AVaccines · 2026Article
- Next-Generation Nanocarrier Platforms for RNA Vaccines: Advances in Formulation, Stability Engineering, and Translational Manufacturing Challenges.Pharmaceutics · 2026Review
- Review
- Transdermal Delivery of an mRNA-Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation.Materials today. Bio · 2026Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lyophilization enhances mRNA vaccine stability, but conventional approaches using external trehalose for lipid nanoparticle (LNP) colloidal stability neglect mRNA chemical degradation and are compromised in vivo efficacy. Here, we report a dual-function trehalose strategy integrating its external and internal roles within LNP. This strategy enables trehalose to externally form a vitrified matrix that preserves LNP colloidal integrity, while internally stabilizing mRNA through hydrogen bonding, markedly reducing chemical degradation during storage compared to LNP relying solely on externally added trehalose. Crucially, co-loaded trehalose is co-delivered into cells, bridging the in vitro-in vivo gap by mitigating oxidative stress through reduced reactive oxygen species (ROS) and malondialdehyde (MDA) alongside elevated glutathione (GSH) and superoxide dismutase (SOD). This is corroborated by downregulated cytoplasmic and nuclear nuclear factor erythroid 2-related factor 2 (Nrf2) expression. Our strategy provides a simple, universally adaptable, and scalable method to enhance mRNA-LNP formulations stability without exogenous components or complex lyophilization steps.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.